anti-transthyretin siRNA ALN-TTR02
Term · Oncology and biomedicine · MLC-T-ONC-011146
A lipid nanoparticle (LNP)-based formulation consisting of small-interfering RNAs (siRNAs) directed against transthyretin (TTR)-encapsulated in lipids, which has potential use in the treatment of TTR-mediated amyloidosis (ATTR). Upon intravenous administration of ALN-TTR02, the lipid formulation promotes the uptake by cells. The siRNAs bind to TTR mRNAs, which may result in the inhibition of both the translation and expression of the TTR protein. ATTR is caused by mutations in the TTR gene and results in the formation of abnormal amyloid proteins that accumulate in and cause damage to various body organs and tissues.
| Identifier | MLC-T-ONC-011146 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | RNAi therapeutic-targeting transthyretin ALN-TTR02 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-011146",
"term": "anti-transthyretin siRNA ALN-TTR02",
"field": "Oncology and biomedicine",
"definition": "A lipid nanoparticle (LNP)-based formulation consisting of small-interfering RNAs (siRNAs) directed against transthyretin (TTR)-encapsulated in lipids, which has potential use in the treatment of TTR-mediated amyloidosis (ATTR). Upon intravenous administration of ALN-TTR02, the lipid formulation promotes the uptake by cells. The siRNAs bind to TTR mRNAs, which may result in the inhibition of both the translation and expression of the TTR protein. ATTR is caused by mutations in the TTR gene and results in the formation of abnormal amyloid proteins that accumulate in and cause damage to various body organs and tissues.",
"synonyms": [
"RNAi therapeutic-targeting transthyretin ALN-TTR02"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/anti-transthyretin-sirna-aln-ttr02/"
}
Record 2,293 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.